1188331-12-5

Basic information

• Product Name: (S)‐6‐((4‐bromobenzyl)oxy)‐2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazine
• Synonyms: (S)‐6‐((4‐bromobenzyl)oxy)‐2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazine
• CAS NO: 1188331-12-5
• Molecular Weight: 354.16
• Mol File: 1188331-12-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (S)‐6‐((4‐bromobenzyl)oxy)‐2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)‐6‐((4‐bromobenzyl)oxy)‐2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazine(1188331-12-5)
• EPA Substance Registry System: (S)‐6‐((4‐bromobenzyl)oxy)‐2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazine(1188331-12-5)

Safety Data

• Hazardous Substances Data: 1188331-12-5(Hazardous Substances Data)

Upstream product

• 187235-08-1 (S)‐2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazin‐6‐ol 
• 589-15-1 1-bromomethyl-4-bromobenzene 

Downstream Products

• 1188917-91-0 N‐(((S)‐3‐(2‐fluoro‐4′‐((((S)‐2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazin‐6‐yl)oxy)methyl)‐[1,1′‐biphenyl]‐4‐yl)‐2‐oxooxazolidin‐5‐yl)methyl)acetamide 
• 1257425-50-5 (6S)-2-nitro-6-({4-[5-(trifluoromethyl)-2-pyridinyl]benzyl}oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1188329-66-9 (6S)-2-nitro-6-{[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 

Relevant articles and documents

Synergistic activity of nitroimidazoleoxazolidinone conjugates against anaerobic bacteria

The introductions of the bicyclic 4nitroimidazole and the oxazolidinone classes of antimicrobial agents represented the most significant advancements in the infectious disease area during the past two decades. Pretomanid, a bicyclic 4nitroimidazole, and linezolid, an oxazolidinone, are also part of a combination regimen approved recently by the US Food and Drug Administration for the treatment of pulmonary, extensively drug resistant (XDR), treatmentintolerant or nonresponsive multidrugresistant (MDR) Mycobacterium tuberculosis (TB). To identify new antimicrobial agents with reduced propensity for the development of resistance, a series of dualacting nitroimidazoleoxazolidinone conjugates were designed, synthesized and evaluated for their antimicrobial activity. Compounds in this conjugate series have shown synergistic activity against a panel of anaerobic bacteria, including those responsible for serious bacterial infections.

NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY

The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES

The current invention provides a series of bicyclic nitroimidazole- substituted phenyl oxazolidinones in which a bicyclic nitroimidazole pharmacophore is covalently bonded to a phenyl oxazolidinone, their pharmaceutical compositions, and the method of use of the compositions for prevention and treatment of bacterial infections. The bicyclic nitroimidazole-substituted phenyl oxazolidinones possess surprising antibacterial activity against wild- type and resistant strains of pathogens, and are therefore useful for the prevention, control and treatment of a number of human and veterinary bacterial infections caused by these pathogens, such as Mycobacterium tuberculosis.